Healthcare Industry News: influenza
News Release - October 25, 2018
Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular ResultsNEW ASSAYS EMPOWER CLINICIANS TO MORE QUICKLY MAKE THE RIGHT DIAGNOSIS AT THE POINT-OF-CARE AND PRESCRIBE THE RIGHT TREATMENT
ABBOTT PARK, Ill., Oct. 25, 2018 -- (Healthcare Sales & Marketing Network) -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has cleared its next-generation influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing1,2. These new assays enable the fastest-ever3 time to molecular influenza A & B and Strep A results at the point of care.4 Currently available on the ID NOW platform (formerly Alere i), both assays have been granted a Clinical Laboratory Improvement Amendments (CLIA) certificate of waiver.
The enhanced influenza A & B 2 assay offers the fastest point-of-care molecular detection and differentiation of influenza A and B virus available in 13 minutes or less, with early call out of positive results in as little as five minutes and allows for room temperature storage of all test components, simplifying and streamlining test ordering and storage.
The Strep A 2 provides molecular detection of Group A Streptococcus bacterial nucleic acid, the primary cause of bacterial pharyngitis (sore throat), more than twice as rapidly as other available molecular tests in six minutes or less, with call out of positive results as early as two minutes with no culture confirmation required for negative results.
"These influenza A & B 2 and Strep A 2 assays combine speed with efficacy for rapid delivery of molecular results, further driving value for healthcare systems where time equals money," said Sharon Bracken, senior vice president, Rapid Diagnostics, Abbott. "By delivering fast and accurate molecular results at the point of care, these tests provide physicians with the confidence to give the right diagnosis and the ability to prescribe the right treatment earlier."
"The ability to obtain early call outs for positive test results with molecular accuracy in as little as five minutes for influenza and two minutes for Strep A is a game-changing development that allows prompt treatment decisions at the point of care," said Gregory J. Berry, Ph.D., Director, Molecular Diagnostics, Northwell Health Laboratories in Lake Success, NY. "Rapid testing may also help reduce improper antibiotic usage, which can occur when treatment is based exclusively on a patient's symptoms, and contributes to antibiotic resistance."
The new assays are available in a broad range of outpatient and inpatient settings where patients are increasingly accessing healthcare services, including emergency rooms, physician offices, walk-in clinics and urgent care centers. Such assays help healthcare providers to make fast, informed diagnosis possible, and linkage to appropriate treatment, during a single patient visit.
ABOUT THE ID NOW (FORMERLY ALERE I) MOLECULAR PLATFORM
ID NOW, the first CLIA-waived point-of-care molecular platform, is a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. Abbott's unique ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing clinicians to make effective clinical decisions during a patient visit. The initial influenza A & B and Strep A assays for the ID NOW platform were cleared in 2014 and 2015, respectively. The third assay on the platform, for respiratory syncytial virus (RSV), was cleared in 2016. Abbott expects to offer ID NOW assays this fall for use with both existing Alere i instruments and new ID NOW instruments.
Each year, a combination of influenza A and B virus strains circulate within the United States. The burden of influenza in the United States is currently estimated to be 9 to 36 million cases per year. The disease and its complications cause as many as 140,000-710,000 hospitalizations and 12,000-56,000 deaths annually. influenza also poses a significant economic burden including medical care expenses and loss of productivity.5
Pharyngitis, or inflammation of the pharynx causing sore throat, is diagnosed in 11 million patients in U.S. emergency departments and ambulatory settings annually.6 Group A streptococcus (GAS) is the most common bacterial cause of acute pharyngitis, accounting for 15 to 30 percent of cases in children and 5 to 20 percent of cases in adults.7 GAS is easily and frequently spread among families and other close contacts via respiratory secretions, and infection peaks in the late winter and early spring.8
At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world in nutrition, diagnostics, medical devices and branded generic pharmaceuticals that create more possibilities for more people at all stages of life. Today, 99,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.
1. influenza A&B 2 assay cleared by the FDA in United States; registrations pending for markets outside U.S.
2. Strep A 2 assay cleared by the FDA in United States; registrations pending for markets outide U.S.
3. influenza A&B rapid molecular test time-to-results in markets where assays cleared. Based on package inserts or other company-produced material in public domain (Abbott Alere i influenza A & B 2: https://www.alere.com/en/home/product-details/alere-i-influenza-ab-2.html; Cepheid Xpert Xpress Flu: http://www.cepheid.com/us/cepheid-solutions/clinical-ivd-tests/critical-infectious-diseases/xpert-xpress-flu; Luminex Corp Aries Flu A/B & RSV assay: https://www.luminexcorp.com/clinical/infectious-disease/aries-flu-ab-rsv-assay/; Quidel Solana influenza A+B Assay: https://www.quidel.com/molecular-diagnostics/solana-influenza-assay; Roche Cobas LIAT influenza A/B Assay: http://www.roche-diagnostics.ch/content/dam/corporate/roche-dia_ch/documents/broschueren/molecular_diagnostics/parameter/07-cobas-liat-system/cobas_Liat_Assay_Strep_A.pdf; Sekisui Silaris influenza A&B Test: https://www.sekisuidiagnostics.com/writable/product_documents/files/silaris60012-c_silaris_ifu_.pdf)
4. Group A Streptococcus bacterial nucleic acid rapid molecular test time-to-results in markets where assays cleared. Based on package inserts or other company-produced material in public domain (Abbott Alere i Strep A 2: https://www.alere.com/en/home/product-details/alere-i-strep-a-2.html; Cepheid Xpert Xpress Strep A: http://www.cepheid.com/us/about-us/news-events/press-releases/316-cepheid-receives-fda-clearance-and-clia-waiver-for-xpert-xpress-strep-a; Luminex Corp Aries Group A Strep: https://www.luminexcorp.com/clinical/infectious-disease/aries-group-a-strep-assay/; Quidel Solana Strep Complete Assay: https://www.quidel.com/sites/default/files/product/documents/PIM305003EN00.pdf; Roche Cobas LIAT: https://usdiagnostics.roche.com/en/point-of-care-testing/poc-testing/infectious-disease/cobas-liat-pcr-system.html)
5. U.S. Centers for Disease Control and Prevention (CDC). Disease burden of influenza. https://www.cdc.gov/flu/about/disease/burden.htm
6. Hing E, Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2003 Summary. Adv Data. 2005;365:148.
7. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH, for the Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin Infect Dis. 2002;35:(2):113125.
8. Danchin MH, Rogers S, Kelpie L, et al. Burden of acute sore throat and group A streptococcal pharyngitis in school-aged children and their families in Australia. Pediatrics. 2007;120(5):950957.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAbbott Receives FDA Emergency Use Authorization for COVID-19 Antibody Blood Test on Alinity(TM) i System
Abbott's TriClip(TM) Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair
Abbott Aims to Optimize TAVI Implants with European Approval of FlexNav(TM) Delivery System for the Company's Portico(TM) Valve